Total
0
Shares
MGC Pharma (ASX:MXC) - Co Founder and Managing Director, Roby Zomer
Co Founder and Managing Director, Roby Zomer
Source: FinFeed
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • MGC Pharmaceuticals’ (MXC) Slovenian production and compounding facility has had its Good Manufacturing Practice (GMP) licence renewed for three years
  • This is a significant milestone for the company, as it confirms its products comply with the strict European standards
  • The renewal allows MGC Pharma to deliver on its target production of 5000 units per month at its Slovenian facility by the start of 2021
  • The company can also continue its research, development, production and manufacturing of its CBD and THC products from the same facility
  • MGC Pharma is steady on the market today and shares are currently trading for 2.2 cents each

MGC Pharmaceuticals’ (MXC) Slovenian production and compounding facility has had its Good Manufacturing Practice (GMP) licence renewed for three years.

This licence is essential for the production and manufacture of pharmacy grade medicinal products.

It also marks a significant milestone for MGC Pharma, as it confirms its products meet the strict European standards.

The licence also delivers certainty on the company’s capacity to manufacture GMP cannabinoid-based medicinal products such as CannEpil and CogniCann from its facility.

“Authorities usually issue GMP licences with a one-year term so receiving a three-year GMP licence is a great achievement and a real testament to the quality of our products, staff and the facility,” Co-Founder and Managing Director Roby Zomer stated.

The renewal now allows MGC Pharma to deliver on its target production of 5000 units per month at the facility in Slovenia by the start of 2021.

The company can also continue its research, development, production and manufacturing of its CBD and THC products from the same facility.

MGC Pharma is steady on the market today and shares are trading for 2.2 cents each at 1:35 pm AEST.

MXC by the numbers
More From The Market Herald
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility
IDT Australia (ASX:IDT) - Chair, Alan Fisher

" IDT Australia (ASX:IDT) signs manufacturing deal with Monash University

IDT Australia (IDT) has entered a master services agreement and services order with Monash University.
Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California.